Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Invitrogen™ CD43 Monoclonal Antibody (eBio84-3C1 (84-3C1)), eBioscience™

Mouse Monoclonal Antibody

Supplier:  Invitrogen™ 14043982

Encompass_Preferred

Catalog No. 50-125-78


Only null left
Edge
Add to Cart

Description

Description

Description: The monoclonal antibody ebio84-3C1 reacts with CD43, which is also known as leukosialin, galactoglycoprotein and sialophorin. CD43 is a sialomucin which like many mucins can have both adhesive and anti-adhesive functions. Expression of CD43 is found on most leukocytes except resting B lymphocytes. Proteolytic processing upon activation decreases surface expression. CD43 is involved in activation of T cells, B cells, NK cells, and monocytes. The counter-receptor for CD43 is CD169/SIGLEC-1, which is expressed on macrophages. Applications Reported: This eBio84-3C1 (84-3C1) antibody has been reported for use in flow cytometric analysis, western blotting, and immunohistochemical staining of formalin-fixed paraffin embedded tissue sections. Applications Tested: This eBio84-3C1 (84-3C1) antibody has been tested by flow cytometric analysis of human peripheral blood cells and by immunohistochemistry of formalin-fixed paraffin embedded human spleen using low pH antigen retreival at less than or equal to 20 μg/mL. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Purity: Greater than 90%, as determined by SDS-PAGE. Aggregation: Less than 10%, as determined by HPLC. Filtration: 0.2 μm post-manufacturing filtered.

CD43 (leukosialin, sialophorin) is a transmembrane mucin-like protein with high negative charge, expressed on the surface of most hematopoietic cells. CD43 contributes to a repulsive barrier that interferes with cellular adhesion, however, in certain cases also promotes leukocyte aggregation. By interaction with actin-binding proteins ezrin and moesin CD43 plays a regulatory role in remodeling T-cell morphology and regulates cell-cell interactions during lymphocyte traffic. CD43 signaling both enhances LFA-1 adhesiveness and counteracts LFA-1 induction via other receptors. Expression of CD43 causes induction of functionally active tumor suppressor p53 protein, but in case of p53 and ARF deficiency CD43 promotes tumor proliferation and viability. CD43 appears to be an important modulator of leukocyte functions. Diseases associated with CD43 dysfunction include Wiscott-Aldrich Syndrome and Adenoid Basal Cell Carcinoma.
TRUSTED_SUSTAINABILITY
Specifications

Specifications

CD43
Monoclonal
0.5 mg/mL
PBS with 0.09% sodium azide; pH 7.2
P16150
SPN
Affinity chromatography
RUO
6693
4°C
Liquid
Flow Cytometry, Immunohistochemistry (Paraffin), Western Blot
eBio84-3C1 (84-3C1)
Unconjugated
SPN
3E8 antigen; A630014B01Rik; B-cell differentiation antigen LP-3; CD43; CD43 cytoplasmic tail; CD43-ct; Galactoglycoprotein; GALGP; gpL115; Leukocyte sialoglycoprotein; leukosialin; leukosianin; LOC101120462; LOW QUALITY PROTEIN: leukosialin; Lsn; Lsn1; Ly48; Ly-48; Lymphocyte antigen 48; sialophorin; sialophorin (gpL115, leukosialin, CD43); sialophorin gpL115; SPN; W3/13 antigen
Mouse
100 μg
Primary
Human
Antibody
IgG1 κ
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Product Certifications
Promotions

Promotions

Product Content Correction

The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.